Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide ('Casodex') EPC Programme

Author： Wirth M.   Iversen P.   McLeod D.   See W.  

Publisher： Elsevier

ISSN： 1569-9056

Source： European Urology Supplements, Vol.1, Iss.7, 2002-10, pp. : 20-25

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomised Comparison of Bicalutamide ('Casodex') 150 mg versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic Prostate Cancer - First Report from the Scandinavian Prostatic Cancer Group Study No. 6

By Iversen P.   Tammela T.L.J.   Vaage S.   Lukkarinen O.   Lodding P.   Bull-Njaa T.   Viitanen J.   Hoisaeter P.   Lundmo P.   Rasmussen F.   Johansson J.-E.   Persson B.-E.   Carroll K.   Scandinavian Prostatic Cancer Group SPCG  

European Urology, Vol. 42, Iss. 3, 2002-09 ,pp. : 204-211

Elsevier

Access to resources Recommend Favorite

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

By Wirth M.   Tyrrell C.   Wallace M.   Delaere K.P.   Sanchez-Chapado M.   Ramon J.   Hetherington J.   Pina F.   Heynes C.F.   Borchers T.M.   Morris T.   Stone A.  

Urology, Vol. 58, Iss. 2, 2001-08 ,pp. : 146-150

Elsevier

Access to resources Recommend Favorite

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

By Iversen P.   Tyrrell C.J.   Kaisary A.V.   Anderson J.B.   Baert L.   Tammela T.   Chamberlain M.   Carroll K.   Gotting-Smith K.   Blackledge G.R.P.  

Urology, Vol. 51, Iss. 3, 1998-03 ,pp. : 389-396

Elsevier

Access to resources Recommend Favorite

Conformal proton therapy for early-stage prostate cancer - long-term results of 1,143 patients from a single institution

By Slater J.D.   Rossi C.J.   Yonemoto L.T.   Reyes-Molyneux N.J.   Bush D.A.   Antoine J.E.   Miller D.W.   Teichman S.L.   Slater J.M.  

Urology, Vol. 53, Iss. 5, 1999-05 ,pp. : 978-983

Elsevier

Access to resources Recommend Favorite

Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins - IGFBP-5 mRNA localization differs from IGFBP-5 protein localization

By Nickerson T.   Pollak M.  

Urology, Vol. 54, Iss. 6, 1999-12 ,pp. : 1120-1125

Elsevier

Access to resources Recommend Favorite